Advertisement
Advertisement
U.S. markets open in 1 hour 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.1000-0.1700 (-5.20%)
At close: 04:00PM EDT
3.1900 +0.09 (+2.90%)
After hours: 04:02PM EDT
Advertisement

Delcath Systems, Inc.

1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States
212 489 2100
https://www.delcath.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees55

Key Executives

NameTitlePayExercisedYear Born
Mr. Gerard J. Michel MBA, MSCEO & Director683.82kN/A1963
Mr. John Purpura M.S.Chief Operating Officer482.56kN/A1961
Dr. Johnny John M.D.Sr. VP Clinical Devel. & Medical Affairs383.63kN/A1964
Mr. Anthony C. DiasVP of Fin.N/AN/A1967
Mr. David HoffmanGen. Counsel, Corp. Sec. & Chief Compliance OfficerN/AN/AN/A
Mr. Robin WaggeSr. VP of Rubenstein AssociatesN/AN/AN/A
Mr. Kevin MuirVP of Commercial OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement